期刊文献+

神经轴突导向分子Sema3A在卵巢癌中的表达及其临床意义 被引量:1

Expression of Sema3A in ovarian cancer and its clinical significance
原文传递
导出
摘要 目的:检测卵巢上皮细胞肿瘤中Sema3A的表达情况,并探讨其与临床病理间的关系,分析Sema3A检测在上皮性卵巢癌诊断中的作用。方法:收集80例卵巢肿瘤石蜡标本,采用免疫组织化学法对不同病理分级的卵巢上皮性肿瘤进行Sema3A检测,并用蛋白印迹法检测Sema3A在另8对新鲜良、恶性卵巢肿瘤组织中的表达变化。结果:免疫组织化学检测结果示,在上皮性卵巢癌(卵巢癌)、上皮性交界性肿瘤(交界性肿瘤)及上皮性良性肿瘤(良性肿瘤)中,Sema3A表达存在差异。卵巢癌中Sema3A的表达与其病理分级(r=-0.624;P<0.001)、组织分类(r=0.311;P=0.028)相关。病理分级(G1、G2、G3)与Sema3A的表达分级呈正相关,不同组织学分级间的Sema3A表达有显著差异(P<0.001);而不同组织学分类的卵巢癌(浆液性乳头状腺癌、子宫内膜样腺癌、透明细胞癌、黏液样腺癌)间Sema3A的表达亦有显著差异(P<0.05)。8对卵巢上皮性良、恶性肿瘤组织的蛋白印迹检测结果与免疫组织化学检测结果完全相符,卵巢良、恶性肿瘤中的Sema3A表达有显著差异(P<0.001)。结论:Sema3A在卵巢癌、卵巢交界性肿瘤及卵巢良性肿瘤中的表达呈明显递降趋势。卵巢癌中Sema3A的表达水平随肿瘤恶性程度增高而增高,表明Sema3A阳性表达在卵巢癌诊断中有一定价值,并可提示肿瘤的恶性程度。 Object: To investigate the expression of Sema3A in human epithelial ovarian tumor and the correlation of Sema3A expression with clinicopathological features. Methods: Expressions of Sema3A in 80 paraffin embedded ovarian tumor samples and 8 fresh ovarian tumor specimens were determined by immunohistochemical staining and Western blotting, respectively. The data were analyzed with SPSS 19.0 software package for x2 test. Results: Immunohistochemical findings revealed that the expression of Sema3A differed in ovarian cancer, transitional cell ovarian tumor and benign ovarian tumor. Sema3A expression was correlated significandy with pathologic stage (Spearman's r=-0.624, P〈0.001) and histologic subtype (Spearman's r=0.311, P〈0.05) of ovarian cancer. Western blotting results of 8 fresh specimens demonstrated similar results. The expression of Sema3A differed significantly between benign ovarian tumor and ovarian cancer (P〈0.001). Conclusions: Expression level of Sema3A decreases gradually from ovarian cancer, transitional cell ovarian tumor to benign ovarian tumor. Sema3A expression increase with the increase in malignancy degree. Expression of Sema3A has certain value for the diagnosis and malignancy degree estimation of ovarian cancer.
出处 《诊断学理论与实践》 2014年第2期182-186,共5页 Journal of Diagnostics Concepts & Practice
基金 南通市课题:社会事业科技创新与示范计划(2012_HS)
关键词 卵巢癌 SEMA3A 诊断 Ovarian cancer Sema3A Diagnosis
  • 相关文献

参考文献16

  • 1Altekruse SF,Kosary CL,Krapcho M,et al.SEER Can-cer Statistics Review,1975-2007[R].Bethesda,MD:Na-tional CancerInstitute.
  • 2Neufeld G,Shraga-Heled N,Lange T,et al.Semaphorins in cancer[J].Front Biosci,2005,10:751-760.
  • 3Kigel B,Varshavsky A,Kessler O,et al.Successful inhi-bition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells[J].PLoS One,2008,3(9):e3287.
  • 4Bouras T,Southey MC,Venter DJ.Overexpression of the steroid receptor coactivator AIBI in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and I-IER2/neu[J].Can-cer Res,2001,61(5):903-907.
  • 5Armes JE,Trute L,White D,et al.Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers:a population-based study [J].Cancer Res,1999,59(8):2011-2017.
  • 6Zhou Y,Gunput RA,Pasterkamp RJ.Semaphorin sig-naling:progress made and promises ahead [J].Trends Biochem Sci,2008,33(4):161-170.
  • 7Neufeld G,Kessler O.The semaphorins:versatile regula-tors of tumour progression and tumour angiogenesis [J].Nat Rev Cancer,2008,8(8):632-645.
  • 8Franco M,Tamagnone L Tyrosine phosphorylation in semaphorin signallinff shifting into overdrive[J].EMBO Rep,2008,9(9):865-871.
  • 9Sun T,Krishnan R,Swiercz JM.Grb2 mediates semaphorin-4D-dependent RhoA inactivation[J].J Cell Sci,2012,125(Pt 15):3557-3567.
  • 10Guttmann-Raviv N,Shraga-Heled N,Varshavsky A,et al.Semaphorin-3A and semaphorin-3F work together to re-pel endothelial cells and to inhibit their survival by in-duction of apoptosis[J].J Biol Chem,2007,282(36):26294-26305.

二级参考文献84

  • 1Lozano E, Betson M, Braga VM. Tumor progression : Small GTPases and loss of cell-cell adhesion [ J ]. Bioessays,2003 ;25 (5) :452-63.
  • 2Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization [J].Cancer Sci,2005 ;96 (7) :379-86.
  • 3Chuang YY ,Trsaa NL,Rusk N ,et al. Role of syaaptojanin 2 in glioma cell migration and invasion [J].Cancer Res,2004 ;64( 22 ) :8271-5.
  • 4Gomez del Pulgar T,Bandres E,Espina C,et al. Differential expression of Racl identifies its target genes and its contribution to progression of colorectal cancer[ J]. Int J Biochem Cell Biol. 2007 ;39(12) :2289-302.
  • 5Collins CS, Hong J, Sapinoso L,et al. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase[ J]. Proe Nail Acad Sei USA ,2006 ; 103 (10 ) :3775-80.
  • 6Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interferencebased therapeutics [J]. Nature ,2009 ;457 (7228) :426-33.
  • 7Lapteva N, Yang AG, Sanders DE ,et al. CXCR4 knockdown by small inteffering RNA abrogates breast tumor growth in vivo[ J]. Cancer Gene Ther, 2005 ; 12 ( 1 ) : 84 -9.
  • 8Liang ZX, Yoon Y, Votaw J, et al. Silencing of CXCR4 blocks breast cancer metastasis [J]. Cancer Res,2005 ;65 (3) :967-71.
  • 9Chen YC, Stamatoyannopoulos G, Song CZ. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro[J]. Cancer Res,2003 ;63(16) :4801-4.
  • 10Engers R, Springer E, Michiels F, et al. Rac affects invasion of human renal cell carcinomas by up-regulating tissue inhibitor of metalloproteinases ( TIMP ) -1 and TIMP-2 expression [ J ]. J Biol Chem, 2001 ; 276 (45) :41889-97.

共引文献9

同被引文献14

  • 1Benjamin Nisman,Vladimir Yutkin,Hovav Nechushtan,Ofer N. Gofrit,Tamar Peretz,Simon Gronowitz,Dov Pode.??Circulating Tumor M2 Pyruvate Kinase and Thymidine Kinase 1 Are Potential Predictors for Disease Recurrence in Renal Cell Carcinoma After Nephrectomy(J)Urology . 2010 (2)
  • 2H. Li,D. Lei,X. Wang,S. Skog,Q. He.??Serum thymidine kinase 1 is a prognostic and monitoring factor in patientswith non-small cell lung cancer(J)Oncology Reports . 2005 (1)
  • 3He Qimin,Fornander Tommy,Johansson Hemming,Johansson Ulla,Hu Guo Zhu,Rutqvist Lars-Erik,Skog Sven.Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Research . 2007
  • 4Pan ZL,Ji XY,Shi YM,et al.Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’’s lymphoma patients. Journal of Cancer Research and Clinical Oncology . 2010
  • 5Mao Y,Wu J,Skog S,et al.Expression of cell proliferating genes inpatients with non-small cell lung cancer by immunohistochemistryand cDNA profiling. Oncology Reports . 2005
  • 6Fujiwaki Ritsuto,Hata Kohkichi,Nakayama Kentaro,Moriyama Masashi,Iwanari Osamu,Katabuchi Hidetaka,Okamura Hitoshi,Sakai Eiichi,Miyazaki Kohji.Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes. International journal of cancer. Journal international du cancer . 2002
  • 7Holdenrieder Stefan,Von Pawel Joachim,Duell Thomas,Feldmann Knut,Raith Hannelore,Schollen Annette,Nagel Dorothea,Stieber Petra.Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer. Anticancer Research . 2010
  • 8Martee L. Hensley.A Step Forward for Two-Step Screening for Ovarian Cancer. Journal of Clinical Oncology . 2010
  • 9钟倩,刘婉敏,芦雅萍,练晓勤,张伟健,王海清,刘芳.5种肿瘤标志物检测在卵巢肿瘤的临床意义[J].中国实验诊断学,2010,14(6):876-878. 被引量:14
  • 10张东妹,徐惠贞,杨景阳.血清HE4及CA125水平检测在早期卵巢恶性肿瘤诊断中的价值[J].中国肿瘤临床与康复,2010,17(4):327-330. 被引量:21

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部